Pharmacological Evaluation Of Withania Somnifera Against Arsenic Induced Nephrotoxicity In Laboratory Rats

Arsenic is a toxic heavy metal and its presence in the environment, particularly in drinking water and food, constitutes a major global health concern [1]. Chronic exposure to arsenic can lead to a multisystemic disorder affecting various organs, with the kidneys being a primary target. The kidney's role in concentrating and excreting toxins makes it particularly vulnerable to arsenic accumulation, leading to severe nephrotoxicity [2]. The pathogenesis of arsenic-induced renal injury is complex, but it is widely accepted that the induction of oxidative stress is the central mechanism. Arsenic generates reactive oxygen species (ROS), which overwhelm the cell's endogenous antioxidant defenses, leading to lipid peroxidation, protein damage, mitochondrial dysfunction, and ultimately, apoptosis and necrosis of renal tubular cells [3,4].

In light of the pivotal role of oxidative stress, therapeutic strategies focusing on antioxidant supplementation have gained significant attention. Natural bioactive compounds from medicinal plants are being explored as safer alternatives to synthetic chelating agents for mitigating heavy metal toxicity [5]. Withania somnifera Dunal, commonly known as Ashwagandha, is a cornerstone of traditional Ayurvedic medicine, revered for its "Rasayana" (rejuvenating) properties. It is widely recognized for its adaptogenic, anti-inflammatory, and potent antioxidant activities [6]. These properties are largely attributed to its complex array of phytochemicals, including withanolides (steroidal lactones), sitoindosides, and various alkaloids, which are effective free radical scavengers [7].

While the neuroprotective and immunomodulatory activities of Withania somnifera are well-documented, its specific protective effects against heavy metal-induced kidney damage are less explored. Therefore, the present study was designed to systematically evaluate the nephroprotective and antioxidant efficacy of a standardized extract of Withania somnifera roots in a sodium arsenite-induced model of renal injury in rats.

2. MATERIALS AND METHODS

Chemicals

A standardized extract of Withania somnifera (containing ≥5% total withanolides, Batch No: FWS1712026) was obtained from Natural Remedies Pvt. Ltd., Bangalore, India. Sodium arsenite (S7400-100G) and Coenzyme Q10 were purchased from Sigma-Aldrich, India. All other chemicals and reagents were of analytical grade. Diagnostic kits for biochemical estimations were obtained from Pathozyme Diagnostics, India.

Experimental Animals

Male Sprague Dawley rats (180-220 g) were procured from Global Bioresearch Solutions Private Limited, Pune. The animals were housed in polypropylene cages under controlled environmental conditions (temperature 25±1 ºC, relative humidity 45-55%, 12h light:12h dark cycle). They were provided with standard food pellets and water ad libitum. The experimental protocol (Approval No: 2168/PO/Re/S/22/CPCSEA) was approved by the Institutional Animal Ethics Committee (IAEC) and conducted according to CPCSEA guidelines.

Experimental Design

After acclimatization, the animals were randomly divided into six groups of six rats each:

• Group I (Normal): Received vehicle (Distilled water, p.o.) daily for 28 days.
• Group II (Arsenic Control): Received sodium arsenite (5 mg/kg, p.o.) daily for 28 days.
• Group III (CoQ10): Received sodium arsenite (5 mg/kg, p.o.) and were co-treated with Coenzyme Q10 (10 mg/kg, p.o.) daily.
• Group IV (WS-50): Received sodium arsenite (5 mg/kg, p.o.) and were co-treated with W. somnifera extract (50 mg/kg, p.o.) daily.
• Group V (WS-100): Received sodium arsenite (5 mg/kg, p.o.) and were co-treated with W. somnifera extract (100 mg/kg, p.o.) daily.
• Group VI (WS-200): Received sodium arsenite (5 mg/kg, p.o.) and were co-treated with W. somnifera extract (200 mg/kg, p.o.) daily.

Biochemical Evaluation

At the end of the 28-day period, animals were placed in metabolic cages for 24-hour urine collection to measure urine output. Blood was then collected via the retro-orbital plexus under light ether anesthesia. Serum was separated by centrifugation at 7000 rpm for 15 min at 4°C. Serum levels of creatinine, blood urea nitrogen (BUN), and uric acid were estimated using commercial diagnostic kits with a UV-visible spectrophotometer (Jasco V-530, Japan). Urine creatinine was also measured. Creatinine clearance (mL/min) was calculated using the standard formula: [Creatinine Clearance = (Urine Creatinine × Urine Volume) / (Serum Creatinine × Time in minutes)].

Renal Oxidative Stress Marker Analysis

Following blood collection, the rats were sacrificed. The kidneys were immediately excised, washed with ice-cold saline, and weighed. A 10% w/v tissue homogenate was prepared in 0.1M Tris-HCl buffer (pH 7.4). The supernatant obtained after centrifugation was used for the estimation of:

• Malondialdehyde (MDA): As a measure of lipid peroxidation, estimated by the method of Slater and Sawyer [8].
• Superoxide Dismutase (SOD): Estimated by the method of Misra and Fridovich [9].
• Reduced Glutathione (GSH): Estimated by the method of Moron et al. [10].
• Nitric Oxide (NO): Estimated as nitrite using the Griess reaction as described by Miranda et al. [11].
• Total Protein: Estimated by the method of Lowry et al. [12] to normalize the antioxidant enzyme levels.

Histopathological Examination

A portion of kidney tissue was fixed in 10% neutral buffered formalin. The tissues were processed, embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin (H&E). The stained sections were examined under a light microscope (Nikon E200) for histopathological changes.

Statistical Analysis

All data are presented as mean ± SEM (n=6). The data were analyzed using one-way analysis of variance (ANOVA) followed by Dunnett’s test for multiple comparisons using GraphPad Prism 5.0 software. A p-value < 0.05 was considered statistically significant.

3. RESULTS

The results of this investigation provide a comprehensive and compelling account of the nephroprotective capacity of the standardized Withania somnifera extract against sodium arsenite-induced renal damage. The foundational step of this evaluation involved the successful induction of a severe and reproducible state of acute toxic nephropathy in the Arsenic Control group. This group exhibited statistically significant and pathologically profound derangements across the entire spectrum of measured parameters—from systemic physiological changes to organ-specific biochemical and structural damage—when benchmarked against the healthy Normal Control animals. This successfully established a validated pathological phenotype, providing a rigorous baseline from which the therapeutic efficacy of the interventions could be quantitatively judged.

Against this backdrop of severe toxicity, a clear, classical pharmacological dose-response relationship was unequivocally established for the Withania somnifera extract. The lowest dose of 50 mg/kg proved to be sub-therapeutic, failing to elicit any statistically significant amelioration of the arsenic-induced damage. In contrast, the 100 mg/kg dose demonstrated a partial but significant protective effect, mitigating several key markers of renal dysfunction and oxidative stress. The most robust protection was conferred by the highest dose of 200 mg/kg, which not only reversed the toxic insults to a profound degree but also demonstrated an efficacy profile that closely approached, and in several key parameters was statistically indistinguishable from, that of the positive control group treated with Coenzyme Q10, a clinically relevant antioxidant. The subsequent sections will systematically dissect and present the quantitative and qualitative data that underpin these overarching observations, beginning with the systemic physiological changes and progressing through the serum and tissue-level biochemical analyses, to the definitive corroborative evidence provided by histopathological examination.

animals.

 

 

Fig 3.1 Effect of withania somnifera on Arsenic-induced alteration in body weight

Table 2: Effect of withania somnifera on renal oxidative stress markers

Parameter	Normal	Arsenic Control	CoQ10 (10 mg/kg)	WS (50 mg/kg)	WS (100 mg/kg)	WS (200 mg/kg)
SOD (U/mg protein)	10.91 ± 0.70	3.97 ± 0.45<sup>###</sup>	10.86 ± 0.46<sup>***</sup>	4.12 ± 0.65	5.98 ± 0.76<sup>**</sup>	7.53 ± 0.57<sup>***</sup>
GSH (µg/mg protein)	48.36 ± 1.78	16.02 ± 1.66<sup>###</sup>	40.02 ± 3.24<sup>***</sup>	17.48 ± 2.49	26.64 ± 3.05<sup>**</sup>	34.33 ± 3.23<sup>***</sup>
MDA (nM/mg protein)	4.03 ± 0.21	8.49 ± 0.26<sup>###</sup>	4.94 ± 0.26<sup>***</sup>	8.27 ± 0.40	6.96 ± 0.19<sup>**</sup>	5.78 ± 0.23<sup>***</sup>
Nitric Oxide (µg/mL)	104.10 ± 2.27	335.30 ± 3.95<sup>###</sup>	155.60 ± 2.90<sup>***</sup>	324.50 ± 3.12	279.10 ± 3.78<sup>**</sup>	185.90 ± 3.28<sup>***</sup>
Data are Mean ± SEM (n=6). <sup>###</sup>p < 0.001 vs Normal Control. <sup></sup>p < 0.01, <sup></sup>p < 0.001 vs Arsenic Control.*

 

 

Fig 3.2 Effect of withania somnifera on Arsenic-induced alteration in absolute and relative kidney weights

 

 

Fig. 3.3 Effect of withania somnifera on Arsenic-induced alteration in Serum and urine creatinine levels

 

 

Fig. 3.4 Effect of withania somnifera on Arsenic-induced alteration in BUN and Uric acid levels

 

 

Fig. 3.5 Effect of withania somnifera on Arsenic-induced alteration in urine output and creatinine clearance level

 

 

Fig. 3.6 Effect of withania somnifera on Arsenic-induced alteration in renal total protein level

 

 

Fig. 3.7 Effect of withania somnifera on Arsenic-induced alteration in renal SOD and GSH level

 

 

Fig. 3.8 Effect of withania somnifera on Arsenic-induced alteration in renal MDA and NO level

 

 

Fig. 3.9 Histopathological representation of renal tissue from normal rats (A), Arsenic Control rats (B), Coenzyme Q10 (10 mg/kg) treated rats (C), XX (100 and 200 mg/kg) treated rats (D). Stained with H&E (at 100 X).

4. DISCUSSION

The findings from this study provide a robust, multi-faceted confirmation of the severe nephrotoxicity induced by chronic sodium arsenite administration and, more importantly, highlight the potent protective efficacy of Withania somnifera. The experimental model successfully replicated the key features of arsenic-induced renal injury. The dramatic increase in kidney weight in the toxicant group is a clear sign of inflammation and oedema, a pathological response to cellular injury [13]. This was functionally validated by the sharp decline in renal performance, as evidenced by the accumulation of nitrogenous waste products (creatinine, BUN, uric acid) in the serum and the drastic reduction in the kidney's ability to clear creatinine from the plasma.

The mechanistic underpinning of this renal failure was clearly demonstrated to be oxidative stress. The arsenic-induced cascade of ROS generation overwhelmed the kidney's natural antioxidant defenses, leading to the depletion of SOD and GSH. SOD represents the first line of enzymatic defense against the highly damaging superoxide radical, while GSH is the most abundant intracellular non-enzymatic antioxidant, critical for neutralizing a wide range of free radicals and detoxifying xenobiotics [3,4]. The depletion of these crucial protectors left the renal cells defenseless against oxidative attack, leading to widespread lipid peroxidation of cell membranes, as confirmed by the elevated MDA levels. This membrane damage disrupts cellular integrity and function, ultimately culminating in the necrotic cell death observed in the histopathological analysis.

The therapeutic intervention with the standardized extract of Withania somnifera proved to be highly effective. The extract's ability to dose-dependently ameliorate all the measured parameters points to a powerful and authentic pharmacological effect. The core of this protective action is unequivocally its antioxidant capacity. By restoring the depleted SOD and GSH levels, the extract effectively re-armed the kidney's antioxidant shield. Concurrently, by significantly reducing MDA and NO levels, it demonstrated its ability to either directly scavenge free radicals or prevent their formation, thereby halting the destructive cascade of oxidative damage. This restoration of cellular redox homeostasis is the key to its nephroprotective effect, as it prevents the cellular damage that leads to functional decline.

The potent antioxidant activity of Withania somnifera is well-supported by its known phytochemical composition. The extract is a rich source of withanolides, flavonoids, and other phenolic compounds, which are known to be powerful free radical scavengers [6,7]. Beyond direct scavenging, many of these compounds are also known to be activators of the Nrf2-ARE pathway, the master regulator of cellular antioxidant responses [14]. Activation of this pathway leads to the coordinated upregulation of a vast array of protective genes, including those responsible for the synthesis and regeneration of GSH. Therefore, it is plausible that W. somnifera exerts its effects through both direct radical scavenging and by bolstering the kidney's intrinsic defense mechanisms.

The comparable efficacy of the 200 mg/kg dose of the extract to Coenzyme Q10, a well-known mitochondrial antioxidant, further strengthens this conclusion. The clear dose-dependency, with the 50 mg/kg dose being ineffective, indicates that a sufficient concentration of the bioactive compounds is necessary to overcome the severe toxic insult from arsenic.

CONCLUSION

In conclusion, the standardized hydroalcoholic extract of Withania somnifera roots exhibits potent nephroprotective activity against sodium arsenite-induced renal damage in rats. This effect is strongly associated with its ability to ameliorate oxidative stress by restoring endogenous antioxidant enzymes and inhibiting lipid peroxidation. These findings highlight the therapeutic potential of Withania somnifera as a natural agent for mitigating the toxic effects of environmental heavy metals. Further research to isolate the specific active constituents and to elucidate their detailed molecular mechanisms is warranted.

REFERENCES

1. Järup L. Hazards of heavy metal contamination. Br Med Bull. 2003;68:167-182.
2. Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ. Heavy metal toxicity and the environment. EXS. 2012;101:133-164.
3. Flora SJS. Arsenic-induced oxidative stress and its reversibility. Free Radic Biol Med. 2011;51(2):257-281.
4. Robles-Osorio ML, Sabath-Silva E, Sabath E. Arsenic-mediated nephrotoxicity. Renal Failure. 2015;37(4):542-547.
5. Patra RC, Swarup D, Dwivedi SK. Antioxidant effects of α-tocopherol, ascorbic acid and L-methionine on lead induced oxidative stress in the liver and kidney of rats. Toxicology. 2001;162(2):81-88.
6. Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5S):208-213.
7. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009;14(7):2373-2393.
8. Slater TF, Sawyer BC. The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J. 1971;123(5):805-814.
9. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247(10):3170-3175.
10. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582(1):67-78.
11. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5(1):62-71.
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-275.
13. Ferguson MA, Waikar SS, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2012;52:293-311.
14. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1–Nrf2–ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89-116